1 / 3

PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke)

PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke). VY Reddy (Mount Sinai School of Medicine, New York, NY) Heart Rhythm Society (HRS) 2013 Scientific Sessions.

hada
Download Presentation

PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) VY Reddy (Mount Sinai School of Medicine, New York, NY) Heart Rhythm Society (HRS) 2013 Scientific Sessions • A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin for LAA closure with respect to all-cause and CV mortality and hemorrhagic stroke in patients with nonvalvular atrial fibrillation and stroke risk factors • Population and treatment: • 800 patients followed up for a mean of 45 months, or an aggregate of 2621 patient-years, randomized to either the Watchman device or warfarin • Primary end points: • Efficacy: Stroke, systemic embolism, or CV or unexplained death • Safety: A composite of serious pericardial effusion, major bleeding, procedure-related stroke, hemorrhagic stroke, and device embolization LAA=Left Atrial Appendage

  2. PROTECT-AF: Results Rate ratios for primary efficacy and safety end points and secondary end points in PROTECT-AF, by intention to treat • The new data confirm that the Watchman is noninferior and show for the first time that it is superior to warfarin for the composite primary efficacy end point of stroke, systemic embolism, or cardiovascular or unexplained death. • LAA closure with the Watchman device is superior to warfarin with respect to all-cause and CV mortality and hemorrhagic stroke in patients with nonvalvular atrial fibrillation and stroke risk factors. • The observed 40% drop in primary events were fairly consistent throughout most of the trial, but only with the latest long-term analysis reached statistical superiority.

  3. PROTECT-AF: Commentary* • "This is statistically nonsignificant for the first time. The reason is, even though there [was] a high number of [mostly procedure-related] events up front in the Watchman group, there [were] cumulative events in the warfarin group. So by the time we have the four-year analysis, the event rate is statistically similar. • "The difference is that the confidence intervals have narrowed, meaning, as we have more data accumulated, we have become more and more confident that that 40% decrease is actually . . . a real end point, not just by chance. The amount of benefit hasn't really changed; what has changed is our certainty that the number is really true." - Dr Vivek Y Reddy *All comments from Long-term PROTECT-AF analysis: Watchman attains efficacy superiority over warfarin in AF(http://www.theheart.org/article/1538469.do)

More Related